Virtual Library
Start Your Search
Dimitrios Exarchos
Author of
-
+
EP1.12 - Small Cell Lung Cancer/NET (ID 202)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Small Cell Lung Cancer/NET
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.12-14 - Multiple Primary Malignant Neoplasms in Patients with Small Cell Lung Cancer. The Experience of Our Center (Now Available) (ID 715)
08:00 - 18:00 | Author(s): Dimitrios Exarchos
- Abstract
Background
Treatment and, mainly, modern diagnostic tools during the first diagnosis of the disease and follow-up, seem to improve survival in patients with small cell lung cancer (SCLC) and thus increase the number of patients diagnosed with multiple primary malignant neoplasms.
Method
The aim of this retrospective study was to estimate and report the incidence of multiple primary malignant neoplasms and discuss the clinical characteristics of this subgroup of patients with SCLC.
The study includes all patients consecutively admitted between 1/1983 -3/2019 at the Department of Medical Oncology, Evangelismos General Hospital, Athens, Hellas.
Result
Five hundred fifty eight patients [386(69%) men, 172(31%) women, 285(51%) with limited and 273(49%) with extended disease] were included in the study. Median age was 63 (33-87)years, median ECOG was 2 (0-4) and median time of follow-up was 18+ (1+ - 696+) months. Three hundred ninety six (71%) had a short period of follow-up ≤24 months (group A), while 162 had a period of follow-up >24 months (group B). Multiple primary malignant neoplasms were detected in 23(4%) patients, 20(5%) men and 3 (2%) women (p<0.05), synchronous in 11(48%) and metachronous in 12(52%) patients, p=NS. The second malignant neoplasms were lung adenocarcinoma, squamous cell lung carcinoma, colon adenocarcinoma, bladder transitional cell carcinoma, head and neck squamous cell carcinoma, prostate adenocarcinoma, NHL, and thyroid follicular carcinoma in 7, 5, 4, 3, 2, 1 and 1 cases respectively. In the group of the 285 patients with limited disease 16(6%) multiple primary malignant neoplasms were observed in relation to 7/273(2.5%) of the patients with extensive disease (0.01< p<0.05). The multiple primary neoplasms were 12/396(3%) and 11/162(7%), p <0.05 in patients of the groups A and B respectively.
Conclusion
1. Development of multiple primary malignant carcinomas in patients with SCLC, does not seem to be a rare phenomenon. 2. The great majority of the multiple primary carcinomas (lung adenocarcinomas, squamous cell lung carcinomas, bladder transitional cell carcinomas, head / neck carcinomas) is smoking dependent. 3. The risk was higher in males, in patients with limited disease and in those surviving more than 24 months.
